PMID- 29779086
OWN - NLM
STAT- MEDLINE
DCOM- 20181127
LR  - 20181202
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Linking)
VI  - 139
IP  - 3
DP  - 2018 Sep
TI  - Retrospective study of nivolumab for patients with recurrent high grade gliomas.
PG  - 625-631
LID - 10.1007/s11060-018-2907-4 [doi]
AB  - INTRODUCTION: Patients with recurrent high-grade gliomas (HGG) have limited 
      treatment options. HGG utilize the PD-1 pathway to evade immune responses. 
      Checkpoint inhibitors have demonstrated safety and clinical activity in patients 
      with recurrent glioblastoma. We explored the efficacy of nivolumab in recurrent 
      HGG with a primary objective of progression free survival (PFS) and overall 
      survival (OS). METHODS: We retrospectively analyzed HGG patients treated with 
      nivolumab in our institution. We included patients with advanced HGG who received 
      nivolumab at their oncologist's decision. Patients received nivolumab 3 mg/kg 
      every 2 weeks until confirmed progression, intolerable toxicity, death, or 
      physician decision. Radiographic assessments were performed every 8 weeks. 
      RESULTS: Between April 2015 and October 2017, 50 HGG patients received nivolumab. 
      43 patients received nivolumab with bevacizumab. 44 patients were bevacizumab 
      refractory and 7 patients received nivolumab monotherapy. All had received prior 
      radiation and chemotherapy. 39 adverse events (AEs) were noted [most commonly 
      fatigue (16%) and constipation (10%)]. 4 (8%) patients experienced grade 3-4 AEs. 
      36 (72%) patients experienced stable disease (SD) at the 2-month assessment. 
      Median duration of SD was 4.3 months (5.1 months in the bevacizumab naive, 3.8 
      months in the bevacizumab refractory). Median PFS was 4.3 months (95% CI 
      3.5-5.3); median OS was 6.5 months (95% CI 6.0-8.8). CONCLUSION: Treatment with 
      nivolumab therapy was associated with a manageable safety profile. In a subset of 
      patients, there was disease stabilization in heavily pre-treated recurrent HGG.
FAU - Mantica, Megan
AU  - Mantica M
AUID- ORCID: 0000-0002-6107-6696
AD  - Division of Hematology-Oncology, Departments of Neurology and Medicine, 
      University of Pittsburgh Medical Center, 5150 Centre Avenue, Pittsburgh, PA, 
      15232, USA. manticam@upmc.edu.
FAU - Pritchard, Ashley
AU  - Pritchard A
AD  - Division of Hematology-Oncology, Departments of Neurology and Medicine, 
      University of Pittsburgh Medical Center, 5115 Centre Avenue, Pittsburgh, PA, 
      15232, USA.
FAU - Lieberman, Frank
AU  - Lieberman F
AD  - Division of Hematology-Oncology, University of Pittsburgh Medical Center, 5150 
      Centre Avenue, Pittsburgh, PA, 15232, USA.
FAU - Drappatz, Jan
AU  - Drappatz J
AD  - Division of Hematology-Oncology, University of Pittsburgh Medical Center, 5150 
      Centre Avenue, Pittsburgh, PA, 15232, USA.
LA  - eng
PT  - Journal Article
DEP - 20180519
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/mortality/pathology
MH  - Female
MH  - Glioma/*drug therapy/mortality/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local/*drug therapy/mortality/pathology
MH  - Nivolumab
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Bevacizumab
OT  - Glioblastoma
OT  - High-grade Glioma
OT  - Nivolumab
OT  - Refractory
EDAT- 2018/05/21 06:00
MHDA- 2018/11/28 06:00
CRDT- 2018/05/21 06:00
PHST- 2018/02/06 00:00 [received]
PHST- 2018/05/16 00:00 [accepted]
PHST- 2018/05/21 06:00 [pubmed]
PHST- 2018/11/28 06:00 [medline]
PHST- 2018/05/21 06:00 [entrez]
AID - 10.1007/s11060-018-2907-4 [pii]
AID - 10.1007/s11060-018-2907-4 [doi]
PST - ppublish
SO  - J Neurooncol. 2018 Sep;139(3):625-631. doi: 10.1007/s11060-018-2907-4. Epub 2018 
      May 19.